Search results for "slas europe 2018"

Clinical laboratories can immediately begin using this kit to detect SARS-CoV-2

SARS-CoV-2 Nucleocapsid, clone 502 Monoclonal Antibody (matched pair with clone 504)

SARS-CoV-2 Nucleocapsid, clone 503 Monoclonal Antibody (matched pair with clone 504)

COVID-19, MERS & SARS-CoV, Nucleoprotein Antibody, 1057

SARS-CoV-2 Nucleocapsid, clone 504 Monoclonal Antibody (matched pair with clone 502 or 503)

SARS-CoV-2 Nucleocapsid, clone 2A1 Monoclonal Antibody (matched pair with clone 2C1)

SARS-CoV-2 Nucleocapsid, clone 2C1 Monoclonal Antibody (matched pair with clone 2A1)

SARS-CoV-2 Nucleocapsid, clone 4D8 Monoclonal Antibody (matched pair with clone 5B7)

SARS-CoV-2 Nucleocapsid, clone 5B7 Monoclonal Antibody (matched pair with clone 4D8)

SARS-CoV-2 Nucleocapsid,clone 7B3 Monoclonal Antibody (matched pair with clone 5D4)

SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 613

SARS-CoV-2 Spike (RBD, aa 331-524) Recombinant Antigen

SARS-CoV-2 Spike Protein S1 (aa 1-674) Recombinant Antigen

Leveraging antibody-based proteomics in protein quantitative trait loci mapping for disease research

Researchers at Manchester and York universities have highlighted the disparity in the impact of the COVID-19 pandemic

University of Manchester researchers share findings from a study into the use of locum GPs in England

CSF-1 pathway inhibitor; Inhibits cFMS

Scientists at the National Center for Research on Human Genomics are at the forefront of groundbreaking research to develop new drugs for major diseases

Merck's immuno-oncology cell lines are innovative research tools for biologics discovery and clinical development. These are the perfect cell-based assay tools you need for the entire drug discovery and clinical development process. Whether you need screening tools for CAR/TCR therapies and mAB development, target cells for efficacy testing, or potency assays for clinical development, Merck provides functional biologically-re…

Curetis and MGI's collaboration will enable short-term commercialisation of NGS-based molecular microbiology.